ASCO GU|RemeGen Announced Highly Encouraging Data from the Phase II Clinical Trial Evaluating Disitamab Vedotin plus Immunotherapy as Perioperative Regimen for Bladder Cancer

Rate this post




Asco Guïremegen announced a highly promotional data from a phase clinical trial, assessing Disitamab Vedotin Plus Immunotherapy as a peroferative mode of bladder cancer

 
Report

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *